← Evidence map

ArticleHealth services insights2020

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II.

Enrico Torre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II. | Socratic